Mouse VEGF-D Biotinylated Antibody

Catalog #: BAF469 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
BAF469

All VEGF-D Antibodies

Product Details

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse VEGF-D Biotinylated Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse VEGF-D in ELISAs and Western blots. In sandwich immunoassays, less than 75% cross-reactivity with recombinant human (rh) VEGF-D is observed and less than 0.1% cross-reactivity with recombinant mouse (rm) VEGF, rmVEGF-B, and rhVEGF-C is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant mouse VEGF-D
Phe98-Ser206
Accession # P97946

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Label

Biotin

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Mouse VEGF-D (Catalog # 469-VD)

Mouse VEGF-D Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Detection (Matched Antibody Pair)

0.1-0.4 µg/mL

Use in combination with:

Capture Reagent: Mouse VEGF‑D Antibody (Catalog # MAB469)

Standard: Recombinant Mouse VEGF-D Protein (Catalog # 469-VD)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF-D

Vascular endothelia growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cysteine-knot structure (1‑3). VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C-terminal propeptide extensions around the VEGF homology domain (VHD) (1, 2). Proteolytic processing of either 358 aa or 326 aa splice forms of mouse VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD (4‑7). Mature mouse VEGF-D shares 94%, 99%, 93%, 91% and 89% aa identity with the VHD of human, rat, equine, canine and bovine VEGF-D, respectively. It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin (1 - 4). Mouse and human VEGF-D are ligands for VEGF receptor 3 (VEGF-R3, also called Flt-4) that are active across species and show enhanced affinity when processed (8). Unlike human VEGF-D, which is also a ligand for VEGF-R2 (also called Flk-1 or KDR), mouse VEGF-D does not bind to VEGF-R2 (8). VEGF-R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium (1, 2). While VEGF-C is the critical ligand for VEGF-R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth (9‑11). Both promote tumor lymphangiogenesis (12). Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF-R3 signaling in lymphangiogenesis, while binding to integrin alpha 9 beta 1 mediates endothelial cell adhesion and migration (13, 14).

References

Roy, H. et al. (2006) FEBS Lett. 580:2879.
Otrock, Z.H. et al. (2007) Blood Cells Mol. Dis. 38:258.
Orlandini, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11675.
Stacker, S.A. et al. (1999) J. Biol. Chem. 274:32127.
McColl, B.K. et al. (2003) J. Exp. Med. 198:863.
McColl, B.K. et al. (2007) FASEB J. 21:1088.
Baldwin, M.E. et al. (2001) J. Biol. Chem. 276:44307.
Baldwin, M.E. et al. (2001) J. Biol. Chem. 276:19166.
Baldwin, M.E. et al. (2005) Mol. Cell. Biol. 25:2441.
Karpanen, T. et al. (2006) Am. J. Pathol. 169:708.
Orlandini, M. et al. (2006) J. Biol. Chem. 281:17961.
Stacker, S.A. et al. (2001) Nature Med. 7:186.
Karpanen, T. et al. (2006) FASEB J. 20:1462.
Vlahakis, N.E. et al. (2005) J. Biol. Chem. 280:4544.

Long Name

Vascular Endothelial Growth Factor D/cFos-induced Growth Factor

Entrez Gene IDs

2277 (Human); 14205 (Mouse)

Alternate Names

c-fos induced growth factor (vascular endothelial growth factor D); FIGF; vascular endothelial growth factor D; VEGFD; VEGF-D; VEGF-DVEGFDc-Fos-induced growth factor